In an international phase 1--2 clinical trial of patients with immune thrombocytopenia, an oral investigational drug called rilzabrutinib was active and associated with only low-level toxic effects at all dose levels.
from Top Health News -- ScienceDaily https://ift.tt/a1xsB4d
via IFTTT
No comments:
Post a Comment